Home of Hepatology7 rue Daubin1203 GenevaSwitzerland+41 22 807 03 60easloffice@easloffice.eu© 2025 EASL. All rights reserved.Website by Soto.Privacy Policy | Cookie Policy | Terms & Conditions | Cyber Security Explore offerUnlock the full potential of being part of the EASLcommunity. As a member, you’ll gain access toexclusive resources, reduced event fees, top-tierjournals, and professional development opportunitiesdesigned to support your career in hepatologyBecome a memberNurses & Allied Health ProfessionalsLink titleYoung InvestigatorsLink titleBasic ScienceLink titleTitle here Lorem ipsum At the heart of EASL is a diverse and dynamic international community of professionals dedicated to advancing hepatology.Discover how you can get involved and make an impact.Whether you're a member, a Young Investigator, a nurse or allied health professional, or focused on basic science, there's a place for you here. Explore the different pathways to connect, grow and contribute, from membership benefits to tailored programmes and scientific networksLorem ipsum dolor sit ipsum CommunitySign In / Sign UpResourcesWhat We DoAbout Us Partnerships

Media

Press and media

EASL collaborates with a range of trusted media partners to amplify the reach of liver science and share the latest developments in hepatology with a wider audience. Through these partnerships, we promote EASL events, publications and initiatives, while supporting accurate, high-quality coverage of advances in liver research and care. If you are a media outlet interested in covering EASL activities or becoming a media partner, we invite you to get in touch with us.

Media

Press Releases

EASL-ESCMID Position Paper: Patients with advanced liver disease and transplant recipients require specific care during COVID-19

The European Association for the Study of the Liver (EASL) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) have issued a Position…

Global hepatology societies call for better HCV testing and access to treatment

Four societies focused on liver disease research and treatment announced a global call-to-action initiative to simplify hepatitis C testing and treatment. BOSTON, 8 November 2019….

Obesity epidemic results in Non-Alcoholic Fatty Liver Disease (NAFLD) becoming the most common cause of liver disease in Europe.

World´s leading experts gather in Seville to discuss the fastest growing health epidemic in Europe now affecting 1 in 4 people. 26 September 2019 –…

LITMUS – Progress towards diagnosing and better treating liver disease

A pioneering European research project, designed to develop new diagnostic tests to assess patients with Non-Alcoholic Fatty Liver Disease (NAFLD) has expanded giving access to…

EASL Governing Board appoints Ben Hainsworth as incoming Managing Director

Starting September 2019 Hainsworth will serve as the interface between the EASL Governing Board and the organisation`s Geneva and Brussels operations, ensuring high quality and…

Journal of Hepatology achieves best ranked publication on liver disease

GENEVA, Switzerland Last week, ClarivateTM Analytics released the 2019 update of its Journal Citation Reports©, including the much anticipated 2018 impact factor. EASL’s flagship monthly…

Genetic analysis has potential to transform diagnosis and treatment of adults with liver disease of unknown cause

Whole-exome sequencing successfully diagnosed genetic cause of liver disease in one in four adults and could play a key role in timely diagnosis and treatment…

Treatment with high doses of albumin improves cardiac function and reduces systemic inflammation in patients with decompensated cirrhosis

According to a study conducted by the EF-Clif published in Gastroenterology This study has shown for the first time that the administration of albumin at…

The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia

A revision is proposed for current WHO guidelines for chronic hepatitis B (CHB) as they fail to detect half of the patients in need of…

Antiviral therapy improves survival rates for kidney transplant recipients with hepatitis B or C

In a new study in the Journal of Hepatology, researchers report favorable 10-year survival rates for patients with HBV and/or HCV treated with antiviral agents…
Scroll to Top

Search EASL